Clinically relevant drug interactions of current antifungal agents

Mycoses

Volumn 53, Issue 2, 2010, Pages 95-113

  Gubbins, Paul O ^a   Heldenbrand, Seth ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antifungal pharmacokinetics; Drug interactions; Drug metabolism and transport proteins; Echinocandins; Polyenes; Triazoles

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CARRIER PROTEIN; CASPOFUNGIN; CISPLATIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETO ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; N DESAKYLITRACONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; RAPAMYCIN; TACROLIMUS; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ACTIVE TRANSPORT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CARDIOMEGALY; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG TRANSFORMATION; ELECTROLYTE DISTURBANCE; HUMAN; HYPOKALEMIA; KIDNEY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICINE; NEPHROTOXICITY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; TABLET FORMULATION; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CRITICAL ILLNESS; DRUG INTERACTIONS; HUMANS; MYCOSES;

EID: 76749132118     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01820.x     Document Type: Review

References (160)

1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990 12 : 308 329.
2. Bekersky I, Fielding RH, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002 46 : 834 840.
3. Bekersky I, Fielding RH, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002 46 : 828 833.
4. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005 6 : 2231 2243.
5. Stone JA, Xu X, Winchell GA et al. Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004 48 : 815 823.
6. Sandhu P, Lee W, Xu X et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005 33 : 676 682.
7. Balani SK, Xu X, Arison BH et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000 28 : 1274 1278.
8. Hebert MF, Smith HE, Marbury TC et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005 45 : 1145 1152.
9. Cappelletty D, Eiselstein-McKitrick K. The echioncandins. Pharmacotherapy 2007 27 : 369 388.
10. Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007 27 : 53 67.
11. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome p450 interactions of anidulafungin. Antimicrob Agent Chemother 2009 53 : 1149 1156.
12. Estes KE, Penzak SR, Calis KA, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009 29 : 17 30.
13. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997 33 : 52 77.
14. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005 28 : 1805 1808. (Pubitemid 41324160)
15. Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM. Glucuronidation of 3-azido-3-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, and valproic acid. Antimicrob Agents Chemother 1998 42 : 1592 1596.
16. Uchaipichat V, Winner LK, Mackenzie PL, Elliot DJ, Williams JA, Miners JO. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 2006 61 : 427 439.
17. Wang E, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2001 46 : 160 165.
18. Yasuda K, Lan L, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002 303 : 323 332.
19. Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989 32 (1 Suppl. 67 87.
20. Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003 51 : 453 457.
21. Van de Velde VJ, Van Peer AP, Heykants JJ et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996 16 : 424 428.
22. Barone JA, Moskovitz BL, Guarnieri J et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998 18 : 295 301.
23. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998 42 : 1862 1865.
24. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998 35 : 461 473.
25. Isoherranen N, Kunze KL, Allen KE et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004 32 : 1121 1131.
26. Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006 34 : 583 590.
27. Templeton IE, Thummel KE, Kharasch ED et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008 83 : 77 85.
28. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995 13 : 129 134.
29. Eytan GD, Regev R, Oren G et al. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996 271 : 12897 12902.
30. Ferté J. Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 2000 267 : 277 294.
31. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci 2007 96 : 3226 3235.
32. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002 46 : 2546 2553.
33. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003 56 (Suppl. 1 17 23. (Pubitemid 37491729)
34. Roffey SJ, Cole S, Comby P et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003 31 : 731 741.
35. Donnelly JP, DePauw BE. Voriconazole: a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004 10 (Suppl. 1 107 117.
36. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997 97 : 663 665.
37. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003 31 : 540 547.
38. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004 48 : 2166 2172.
39. Walsh TJ, Driscoll TA, Arietta AC et al. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Hospitalized Children. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco : American Society for Microbiology, 2006 : Abstract M-887.
40. Walsh TJ, Driscoll TA, Groll AH et al. Population Pharmacokinetic (POP-PK) Analysis of Voriconazole (VRC): Developing a Rationale for Dosage in Pediatric Patients. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago : American Society for Microbiology, 2007 : Abstract M-620.
41. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009 53 : 935 944.
42. Purkins L, Wood N, Kleinermans D et al. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 2003 56 (1 Suppl. 45 50.
43. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 47 : 2788 2795.
44. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005 44 : 211 220.
45. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009 53 : 958 966.
46. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003 57 : 218 222.
47. Sansone-Parsons A, Krishna G, Calzetta A et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006 50 : 1881 1883.
48. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007 45 : 1610 1617.
49. Rüping MJGT, Albermann N, Ebinger F et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 2008 62 : 1468 1470.
50. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 48 : 3543 3551.
51. Ghosal A, Hapangama N, Yuan Y et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004 32 : 267 271. (Pubitemid 38176945)
52. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 21 : 645 653.
53. Sansone-Parsons A, Krishna G, Simon J et al. Effects of age, gender, race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007 51 : 495 502.
54. Chung DK, Koenig MG. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Am Rev Respir Dis 1971 103 : 831 841.
55. Vermes A, van der Sijs IH, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000 46 : 86 94.
56. Stamm AM, Diasio RB, Dismukes WE et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987 83 : 236 242.
57. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979 301 : 126 131.
58. Vermes A, Mathôt RAA, van der Sijs IH, Dankert J, Guchelaar HJ. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. Ther Drug Monit 2000 22 : 676 687.
59. Gubbins PO. Mould active azoles: pharmacokinetics, drug interactions in neutropenic hosts. Curr Opin Infect Dis 2007 20 : 579 586.
60. Gubbins PO, McConnell SA, Amsden JR. Drug interactions associated with antifungal agents. In : Piscitelli SC, Rodvold KA (ed Drug Interactions in Infectious Diseases, 2nd edn. Totowa, NJ : Humana Press, 2005 : 289 337.
61. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000 38 : 111 180.
62. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996 82 : 511 516.
63. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998 54 : 53 8.
64. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997 51 : 415 419.
65. Krishna G, Moton A, Ma L et al. Effects of oral posaconazole on the pharmacokinetics of oral and intravenous midazoloam: a phase I randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009 31 : 286 298.
66. Varhe A, OLkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994 56 : 601 607.
67. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996 60 : 326 331.
68. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996 41 : 319 323. (Pubitemid 26114819)
69. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996 42 : 465 470.
70. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006 79 : 362 370.
71. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996 10 : 314 318. (Pubitemid 26228383)
72. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007 63 : 941 949.
73. Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 1996 18 : 124 127. (Pubitemid 26102855)
74. Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol 2003 59 : 615 619.
75. Otsuji Y, Okuyama N, Aoshima T et al. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther Drug Monit 2002 24 : 375 378.
76. Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997 62 : 348 354.
77. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006 12 : 325 334.
78. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998 46 : 271 272.
79. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin Pharmacol Ther 2002 71 : 226 234.
80. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002 46 : 3091 3093.
81. Tintillier M, Kirch L, Goffin E, Cuvelier C, Pochet JM. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005 20 : 664 665.
82. Anonymous. Immunosuppressive drug interactions with anti-infective agents. Am J Transplant 2004 4 (Suppl. 10 164 166.
83. Omar G, Whiting PH, Hawksworth GM et al. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997 19 : 436 445.
84. Mañez R, Martin M, Raman D et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994 57 : 1521 1523.
85. Krüger HU, Schuler U, Zimmermann R et al. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989 24 : 781 786.
86. Canafax DM, Graves NM, Hilligoss DM et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991 51 : 1014 1018.
87. López-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993 27 : 427 430.
88. Osowski CL, Dix SP, Lin LS et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients. Transplantation 1996 61 : 1268 1272.
89. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007 27 : 825 834.
90. Kuypers DR, Claes K, Evenepoel P et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. Transplantation 2005 79 : 737.
91. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006 26 : 289 295. (Pubitemid 43201879)
92. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002 27 : 1477 1478.
93. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006 26 : 1730 1744.
94. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004 36 : 2708 2709.
95. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004 36 : 3226 3228.
96. Marty FM, Lowry CM, Cutler CS et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006 12 : 552 559.
97. Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008 28 : 719 729.
98. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009 25 : 701 707.
99. Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998 64 : 363 368.
100. Lebrun-Vignes B, Archer VC, Diquet B et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001 51 : 443 450.
101. Varis T, Kivistö KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999 85 : 29 32.
102. Varis T, Kivistö KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000 68 : 487 494.
103. Varis T, Kivistö KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000 56 : 57 60.
104. Ghahramani P, Purkins L, Klienermans D, Nichols DJ. The Pharmacokinetics of Voriconazole and its Effect on Prednisolone Disposition. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada : American Society for Microbiology, 2000 : Abstract 842.
105. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivistö KT. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 2002 72 : 362 369.
106. Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A. Systemic levels of inhaled fluticasone in lung transplant recipients. Respiration 2007 74 : 418 422.
107. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 80 : 565 581.
108. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996 60 : 54 61.
109. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998 63 : 332 341.
110. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998 64 : 58 65.
111. Mazzu AL, Lasseter KC, Shamblin EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000 68 : 391 400.
112. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998 46 : 49 53.
113. Ishigam M, Uchiyama M, Kondo T et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions. Pharm Res 2001 18 : 622 631.
114. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003 73 : 322 329.
115. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000 56 : 225 229.
116. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002 58 : 527 531.
117. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003 37 : 1032 1035.
118. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008 100 : 444 446.
119. Kahri J, Valkonen M, Bäcklund T, Vuoristo M, Kivistö KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005 60 : 905 907.
120. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006 97 : S52 60.
121. Jacobsen W, Kirchner G, Hallensleben K et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999 27 : 173 179.
122. Aberg JA. Drug-drug interactions with newer antiretroviral agents. Top HIV Med 2008 16 : 146 150.
123. Cato A, Cao G, Hsu A, Cavenaugh A, Leonard J, Granneman R. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997 25 : 1104 1106.
124. Koks CHW, Crommentuyn KML, Hoetelmans RMW et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001 51 : 631 635.
125. Mikus G, Schöwel V, Drzewinska M et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006 80 : 126 135.
126. Liu P, Grover F, Gandelman K et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007 51 : 3617 3626.
127. von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001 41 : 85 91.
128. Mouly S, Lown KS, Kornhauser D et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002 72 : 1 9.
129. Liu P, Foster G, Labadie RR, Gutierrez MJ, Sharma A. Voriconazole and efavirenz at steady state in healthy male subjects. J Clin Phamacol 2008 48 : 73 84.
130. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008 65 : 523 530.
131. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. BMJ 1990 301 : 669.
132. Black DJ, Kunze KL, Wienkers LC et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996 24 : 422 428.
133. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008 84 : 581 588.
134. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003 56 (Suppl. 1 24 29.
135. Blum RA, Wilton JH, Hilligoss DM et al. Effect of fluconazole on disposition of phenytoin. Clin Pharmacol Ther 1991 49 : 420 425.
136. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003 56 (Suppl. 1 37 44.
137. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007 23 : 1415 1422.
138. de Lannoy IA, Silverman M. The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin. Biochem Biophys Res Comm 1992 189 : 551 557.
139. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997 19 : 609 613.
140. Purkins L, Wood N, Klienermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 2003 56 (Suppl. 1 45 50.
141. Burmúdez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005 27 : 389 392.
142. Bashir H, Motl S, Metzger ML et al. Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma. J Pediatr Hematol Oncol 2006 28 : 33 35.
143. Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol 2007 29 : 130.
144. Eiden C, Palenzuela G, Hillaire-Buys D et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol 2009 31 : 292 295.
145. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer 2009 52 : 298 300.
146. Stone JA, Migoya EM, Hickey L et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004 48 : 4306 4314.
147. Fleisher D, Li C, Zhou Y et al. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999 36 : 233 254.
148. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003 35 : 417 454.
149. Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993 7 : 317 321.
150. Lohinavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 2005 30 : 201 206.
151. May DB, Drew RH, Yedinak KC et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994 14 : 509 513.
152. Damle B, Hess H, Kaul S et al. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Disp 2002 23 : 59 66.
153. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004 48 : 804 808.
154. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003 36 : 630 637.
155. Muijser RBR, Goa KL, Scott LJ. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002 18 : 2655 2664.
156. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993 9 : 309 311.
157. Ducharme MP, Slaughter RL, Warbasse LH et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995 58 : 617 624.
158. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998 54 : 155 158.
159. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007 23 : 545 552. (Pubitemid 46456902)
160. Apseloff G, Hilligoss DM, Gardner MJ et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991 31 : 358 361.